RT Journal Article
SR Electronic
T1 Identification of EPHB4 variants in dilated cardiomyopathy patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.16.22283442
DO 10.1101/2022.12.16.22283442
A1 Luxán, Guillermo
A1 Muhly-Reinholz, Marion
A1 Glaser, Simone F.
A1 Trebing, Johannes
A1 Reich, Christoph
A1 Haas, Jan
A1 Sedaghat-Hamedani, Farbod
A1 Meder, Benjamin
A1 Dimmeler, Stefanie
YR 2023
UL http://medrxiv.org/content/early/2023/10/06/2022.12.16.22283442.abstract
AB Cardiac homeostasis relies on the appropriate provision of nutrients to the working myocardium. EPHB4 is required for the maintenance of vascular integrity and correct fatty acid transport uptake in the heart via regulating the caveolar trafficking of the fatty acid receptor CD36. In the mouse, endothelial specific loss-of-function of the receptor EphB4, or its ligand ephrin-B2, induces Dilated Cardiomyopathy (DCM) like defects. Now, we have identified six new EPHB4 variants with deleterious potential in a cohort of 573 DCM patients. Similar to the EphB4 mutant mice, EPHB4 variants carrying patients show an altered expression pattern of CD36 and CAV1 in the heart. For the first time, our data identifies EPHB4 mutations in DCM patients. This observation supports the notion that the Eph-ephrin signalling pathway, and in particular the receptor EPHB4, plays a role in the development of DCM in human patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the German Centre for Cardiovascular Research (DZHK). Grant UA.0004.21 to G.L.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute for Cardiomyopathies Heidelberg (ICH): Ethical approval has been obtained from the local ethics committee (University of Heidelberg, S-344/2014). TORCH-Plus-DZHK: Ethical approval has been obtained from the leading ethics committee (University of Heidelberg, S-344/2014) and subsequently from all responsible ethics committees of the participating centers involved. ClinicalTrials.gov Identifier: NCT02187263. DRKS-ID (Deutsches Register Klinischer Studien): DRKS00008017. The single-nucleus-RNA-sequencing data set generated in the paper by Nicin et al. (Nicin et al., 2022) (https://www.nature.com/articles/s44161-022-00019-7#Sec9) was used to explore EPHB4 expression in human cardiac cellsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes